Abstract
Annual screening for lung cancer by low-dose computed tomography (LDCT) reduces mortality. Despite no cost-share for covered individuals, limited availability and frequent ‘false alarm’ findings have impeded widespread adoption, diminishing potential population health gains. We examined a model of the clinical and economic effects of introducing an accessible blood-based genomic test (BGT) used as a pre-screen to support more rapid and refined uptake of LDCT screening within the US Medicare population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
